TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20697417

Group type: EXPERIMENTAL
Intervention: HDHK program (n=27 fathers, n=39 children)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: HDHK program
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group (n=26 fathers, n=32 children)
Number of subjects: 53
Study: 19860993

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 0
Study: 16923426

Group type: EXPERIMENTAL
Intervention: Circumferential extraostial PV isolation
Number of subjects: 100

Group type: COMPARATOR
Intervention: Segmental ostial PV isolation
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both strategies
Number of subjects: 100
Study: 12577156

Group type: COMPARATOR
Intervention: Routine endotracheal suctioning (RES)
Number of subjects: 383

Group type: EXPERIMENTAL
Intervention: On-demand minimally invasive airway suctioning (MIAS)
Number of subjects: 383
Study: 11146823

Group type: EXPERIMENTAL
Intervention: Metipranolol
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 8923356

Group type: EXPERIMENTAL
Intervention: sulfasalazine (SSZ)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: gold sodium thiomalate (GSTM)
Number of subjects: 137

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: All patients with RA
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: baseline sIL-2R
Number of subjects: 137
Study: 1402071

Group type: EXPERIMENTAL
Intervention: Piperacillin plus gentamicin
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Piperacillin plus aztreonam
Number of subjects: 32

Group type: COMPARATOR
Intervention: Cefamandole added to non-responders
Number of subjects: 32
Study: 3887852

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 1395

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1395
Study: 30139568

Group type: EXPERIMENTAL
Intervention: Phonophoresis with diclofenac + Thiocolchicoside gel (Group 1)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Ultrasound therapy with non-therapeutic gel (Group 2)
Number of subjects: 60
Study: 29570027

Group type: EXPERIMENTAL
Intervention: Non-silane-pretreated mode
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Silane-pretreated mode
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adhese Universal, Clearfil Universal Bond, Single Bond Universal (all in silane-pretreated mode)
Number of subjects: 0
Study: 26494876

Group type: EXPERIMENTAL
Intervention: 10 mg hydrocortisone
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 25081290

Group type: EXPERIMENTAL
Intervention: 500 mg acetazolamide
Number of subjects: 24

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 24
Study: 22215002

Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 20029243

Group type: EXPERIMENTAL
Intervention: Zaltoprofen 80 mg
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Zaltoprofen 160 mg
Number of subjects: 170

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 170
Study: 18700222

Group type: EXPERIMENTAL
Intervention: 50 mg intravenous diamorphine
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 10 mg subcutaneous hydromorphone
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 16251561

Group type: EXPERIMENTAL
Intervention: Halothane 2, 4, and 6 mL
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Sevoflurane 5 mL
Number of subjects: 30

Group type: COMPARATOR
Intervention: Halothane 1 mL, Isoflurane 1.5 mL, Sevoflurane 2.7 mL
Number of subjects: 30
Study: 12717749

Group type: EXPERIMENTAL
Intervention: Test didanosine formulation (200 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Reference didanosine formulation (200 mg)
Number of subjects: 24
Study: 11077516

Group type: EXPERIMENTAL
Intervention: Increased use of nurses and other health care professionals in diabetes care
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Remuneration for an annual review of patients with diabetes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clarification of the division of work between primary health care and hospital clinics
Number of subjects: 0
Study: 8780566

Group type: EXPERIMENTAL
Intervention: Adrenaline alone (1:100,000)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Adrenaline plus human thrombin (600-1000 IU)
Number of subjects: 140
Study: 1594257

Group type: EXPERIMENTAL
Intervention: PCA group (n = 29)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard treatment group (n = 31)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 6588482

Group type: EXPERIMENTAL
Intervention: Metronidazole alone
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Metronidazole + ampicillin
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Metronidazole + doxycycline
Number of subjects: 136
Study: 30063475

Group type: EXPERIMENTAL
Intervention: Participants told 'this hearing in noise test (HINT) you are about to do is really hard'
Number of subjects: 59

Group type: COMPARATOR
Intervention: Participants told 'this HINT test is really easy'
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Participants comparing 'my setting' to 'another participant'
Number of subjects: 59

Group type: COMPARATOR
Intervention: Participants comparing 'my setting' to 'expert audiologist'
Number of subjects: 59
Study: 29633656

Group type: EXPERIMENTAL
Intervention: Spinal anesthesia (group I)
Number of subjects: 86

Group type: COMPARATOR
Intervention: General anesthesia (group II)
Number of subjects: 86
Study: 25956588

Group type: EXPERIMENTAL
Intervention: Transdermal estradiol (E2) 50 to 200 mcg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sertraline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 23788517

Group type: EXPERIMENTAL
Intervention: 320 mg Bacopa monnieri (BM)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 640 mg Bacopa monnieri (BM)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 22233155

Group type: EXPERIMENTAL
Intervention: Nabilone (1, 2 or 3 mg)
Number of subjects: 30
Study: 21058193

Group type: EXPERIMENTAL
Intervention: Retinol (first quartile)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Isotretinoin (first quartile)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 18272031

Group type: EXPERIMENTAL
Intervention: Sunitinib as maintenance therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16222233

Group type: EXPERIMENTAL
Intervention: Fixed temporal patterning of stimuli
Number of subjects: 0

Group type: COMPARATOR
Intervention: Random interleaving of stimuli
Number of subjects: 0
Study: 11590081

Group type: EXPERIMENTAL
Intervention: Reduction of tobacco exposure by 50% or more
Number of subjects: 1583

Group type: COMPARATOR
Intervention: No change in tobacco exposure
Number of subjects: 1583

Group type: EXPERIMENTAL
Intervention: Third-trimester cigarette use
Number of subjects: 1583

Group type: EXPERIMENTAL
Intervention: Urine cotinine concentration
Number of subjects: 1583
Study: 9237290

Group type: EXPERIMENTAL
Intervention: 1.1% amino acid dialysate (AAD)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Dextrose dialysis
Number of subjects: 18
Study: 8355383

Group type: EXPERIMENTAL
Intervention: Prehospital-initiated treatment (aspirin and alteplase)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Hospital-initiated treatment (aspirin and alteplase)
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Treatment initiated within 70 minutes of symptom onset (both prehospital and hospital)
Number of subjects: 360
Study: 3657877

Group type: EXPERIMENTAL
Intervention: Vi vaccine
Number of subjects: 6907

Group type: COMPARATOR
Intervention: Pneumococcus vaccine (control)
Number of subjects: 6907
Study: 2477300

Group type: EXPERIMENTAL
Intervention: Contact endoscopic laser treatment
Number of subjects: 20

Group type: COMPARATOR
Intervention: Noncontact endoscopic laser treatment
Number of subjects: 20
Study: 2091

Group type: EXPERIMENTAL
Intervention: Anileridine
Number of subjects: 28

Group type: COMPARATOR
Intervention: Pethidine
Number of subjects: 28
Study: 30941731

Group type: EXPERIMENTAL
Intervention: 12-month physiotherapist-supervised home-based physical exercise program (n = 150)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Usual care (n = 150)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 300
Study: 28841561

Group type: EXPERIMENTAL
Intervention: Stochastic Configuration Networks (SCNs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SC algorithms for data regression and classification
Number of subjects: 0
Study: 25770082

Group type: EXPERIMENTAL
Intervention: Endotoxin (inflammatory challenge)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 115
Study: 23574590

Group type: EXPERIMENTAL
Intervention: Drospirenone (DRSP) with ethinyl-estradiol 20 μg (DRSP/EE20)
Number of subjects: 432178

Group type: EXPERIMENTAL
Intervention: Drospirenone (DRSP) with ethinyl-estradiol 30 μg (DRSP/EE30)
Number of subjects: 432178

Group type: COMPARATOR
Intervention: Levonorgestrel (LNG)
Number of subjects: 432178

Group type: EXPERIMENTAL
Intervention: Drospirenone (DRSP)
Number of subjects: 432178
Study: 21651736

Group type: EXPERIMENTAL
Intervention: Hand washing (HW)
Number of subjects: 442

Group type: EXPERIMENTAL
Intervention: Hand washing plus paper surgical face masks (HW + FM)
Number of subjects: 442

Group type: COMPARATOR
Intervention: Control
Number of subjects: 442
Study: 19451831

Group type: EXPERIMENTAL
Intervention: 6-month exercise-based cardiac rehabilitation program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 16397160

Group type: EXPERIMENTAL
Intervention: Targeted promotional tools developed based on audience segmentation
Number of subjects: 0
Study: 14746594

Group type: EXPERIMENTAL
Intervention: Prophylactic scleral buckling with pars plana vitrectomy
Number of subjects: 28

Group type: COMPARATOR
Intervention: Standard three-port pars plana vitrectomy without scleral buckling
Number of subjects: 28
Study: 11385059

Group type: EXPERIMENTAL
Intervention: Vitamin E (250 IU d-alpha tocopherol 3 times daily for 1 year)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo followed by Vitamin E (d-alpha tocopherol for an additional 6 months)
Number of subjects: 44
Study: 9265282

Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg once daily
Number of subjects: 4159

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4159
Study: 8338977

Group type: EXPERIMENTAL
Intervention: 1,25-(OH)2D 0.5 microgram/day for 4 weeks
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 1,25-(OH)2D 0.5 microgram/day + trichlormethiazide (TZ) 2 mg/day for 4 weeks
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (pretreatment)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Long-term treatment with combined 1,25-(OH)2D and TZ for 11-29 months
Number of subjects: 10
Study: 3559779

Group type: COMPARATOR
Intervention: Cardiology textbook chapter on interpreting chest pain
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Prediction rule for estimating probability of coronary artery disease
Number of subjects: 82
Study: 29980352

Group type: EXPERIMENTAL
Intervention: 4% articaine
Number of subjects: 133

Group type: COMPARATOR
Intervention: 2% lidocaine
Number of subjects: 133
Study: 26690066

Group type: EXPERIMENTAL
Intervention: Exercise training/lifestyle intervention (3-month program, mild- to moderate-intensity endurance training, 3-5 times/week, 30-45 min/session, plus strength training, increased salt/water intake)
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Exercise training/lifestyle intervention
Number of subjects: 251
Study: 23584508

Group type: EXPERIMENTAL
Intervention: High hand position
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Positive focus
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: All groups combined
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Expectancy
Number of subjects: 80
Study: 22543739

Group type: EXPERIMENTAL
Intervention: DEH (no fluid replacement)
Number of subjects: 9

Group type: COMPARATOR
Intervention: HYD (fluid replacement)
Number of subjects: 9
Study: 19958308

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CBT)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Paroxetine (40 mg)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Waiting list
Number of subjects: 49
Study: 17645559

Group type: EXPERIMENTAL
Intervention: Caiapo (4 g daily for 5 months)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 17260200

Group type: EXPERIMENTAL
Intervention: Clodronate
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control (no clodronate)
Number of subjects: 50
Study: 12471627

Group type: EXPERIMENTAL
Intervention: Papnet
Number of subjects: 108686

Group type: COMPARATOR
Intervention: Conventional smear
Number of subjects: 108686
Study: 10910310

Group type: EXPERIMENTAL
Intervention: Omeprazole sodium, 20 mg once daily
Number of subjects: 268

Group type: COMPARATOR
Intervention: Ranitidine hydrochloride, 150 mg twice daily
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Omeprazole (8 weeks or more)
Number of subjects: 268

Group type: COMPARATOR
Intervention: Ranitidine (8 weeks or more)
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 268
Study: 9263160

Group type: EXPERIMENTAL
Intervention: morphine (0.3 mg/kg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: lidocaine (5 mg/kg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: ketamine (0.3 mg/kg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: saline (placebo)
Number of subjects: 18

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: responders
Number of subjects: 18
Study: 8501639

Group type: EXPERIMENTAL
Intervention: Healon GV
Number of subjects: 70

Group type: COMPARATOR
Intervention: Healon
Number of subjects: 70
Study: 3307623

Group type: EXPERIMENTAL
Intervention: Oral ribavirin treatment
Number of subjects: 25
Study: 31296264

Group type: EXPERIMENTAL
Intervention: Innovative and stepped structural case management program for depression treatment in nursing home residents.
Number of subjects: 380
Study: 27836532

Group type: EXPERIMENTAL
Intervention: Routine care plus 20 jumps twice daily
Number of subjects: 41

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 41
Study: 25512099

Group type: EXPERIMENTAL
Intervention: Everolimus (n = 46)
Number of subjects: 93

Group type: COMPARATOR
Intervention: CNI (n = 47)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Everolimus (n = 52, subpopulation)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 93

Group type: COMPARATOR
Intervention: CNI
Number of subjects: 93
Study: 23765755

Group type: EXPERIMENTAL
Intervention: Driving training (2 hours after a standard meal)
Number of subjects: 39
Study: 21319341

Group type: EXPERIMENTAL
Intervention: Diacerein treatment group (n = 12)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo group (n = 7)
Number of subjects: 26
Study: 20015431

Group type: EXPERIMENTAL
Intervention: Low dose Yunchang Capsule (0.35 g/pill, 2 pills + 1 simulant pill, three times daily)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: High dose Yunchang Capsule (0.35 g/pill, 3 pills, three times daily)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Control group (Biantong Capsule, 0.35 g/pill, 3 pills, three times daily)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Low dose Yunchang Capsule
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: High dose Yunchang Capsule
Number of subjects: 240

Group type: COMPARATOR
Intervention: Control group (Biantong Capsule)
Number of subjects: 240
Study: 16428355

Group type: COMPARATOR
Intervention: 1 ml sterile water as placebo (group 1, n = 10)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 1 ml 33% sucrose solution (group 2, n = 10)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 1 ml sterile water with pacifier (group 3, n = 9)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 1 ml 33% sucrose solution with pacifier (group 4, n = 11)
Number of subjects: 40
Study: 12893649

Group type: EXPERIMENTAL
Intervention: Prednisolone (40 mg daily)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study: 12847731

Group type: EXPERIMENTAL
Intervention: Pollen immunotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low‐molecular‐weight allergen peptide vaccines
Number of subjects: 0
Study: 8855613

Group type: EXPERIMENTAL
Intervention: Intravenous ondansetron 4 mg
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Both groups (ondansetron and placebo)
Number of subjects: 82
Study: 1625259

Group type: EXPERIMENTAL
Intervention: Channel TURP and bilateral orchidectomy
Number of subjects: 22

Group type: COMPARATOR
Intervention: Bilateral orchidectomy alone
Number of subjects: 22
Study: 6487554

Group type: EXPERIMENTAL
Intervention: Predictive interactions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Reflective interactions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Naive interactions
Number of subjects: 0
Study: 30272637

Group type: EXPERIMENTAL
Intervention: Unmet need for transportation
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: ≥3 unmet subsistence needs
Number of subjects: 417
Study: 29629784

Group type: EXPERIMENTAL
Intervention: Immediate treatment group
Number of subjects: 52

Group type: COMPARATOR
Intervention: Delayed treatment group
Number of subjects: 52
Study: 26864368

Group type: EXPERIMENTAL
Intervention: Whey RUSF (75 kcal · kg(‐1) · d(‐1) for up to 12 weeks)
Number of subjects: 2230

Group type: COMPARATOR
Intervention: Soy RUSF (75 kcal · kg(‐1) · d(‐1) for up to 12 weeks)
Number of subjects: 2230

Group type: EXPERIMENTAL
Intervention: Whey RUSF
Number of subjects: 2230

Group type: COMPARATOR
Intervention: Soy RUSF
Number of subjects: 2230
Study: 24715580

Group type: EXPERIMENTAL
Intervention: TSU-68 plus docetaxel
Number of subjects: 81

Group type: COMPARATOR
Intervention: Docetaxel alone
Number of subjects: 81
Study: 22337952

Group type: EXPERIMENTAL
Intervention: Copeptin and fourth generation cardiac troponin T (cTnT)
Number of subjects: 433

Group type: EXPERIMENTAL
Intervention: Copeptin and high-sensitivity cardiac troponin T (hs-cTnT)
Number of subjects: 433

Group type: EXPERIMENTAL
Intervention: Copeptin
Number of subjects: 433
Study: 21118921

Group type: EXPERIMENTAL
Intervention: + mefloquine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Racemic mefloquine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17563272

Group type: EXPERIMENTAL
Intervention: Clopidogrel loading dose of 300 mg 6-24 hours before intervention and maintenance for 1 month
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clopidogrel treatment continued for at least 24 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clopidogrel maintenance only
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clopidogrel treatment after 6 months from bare-metal stenting
Number of subjects: 0
Study: 15694077

Group type: EXPERIMENTAL
Intervention: Ceiling lift intervention
Number of subjects: 0
Study: 12170167

Group type: EXPERIMENTAL
Intervention: Electroneurography (ENOG)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control group (Group 2)
Number of subjects: 63
Study: 9707350

Group type: EXPERIMENTAL
Intervention: Fludrocortisone (Florinef) therapy for orthostatic hypotension
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: No fludrocortisone therapy
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (healthy elderly persons)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Comparison between non-fludrocortisone Parkinson's patients and fludrocortisone Parkinson's patients
Number of subjects: 41
Study: 9200279

Group type: EXPERIMENTAL
Intervention: 150‐mg ranitidine effervescent tablets
Number of subjects: 377

Group type: COMPARATOR
Intervention: 20‐mg famotidine wafers
Number of subjects: 377
Study: 2293218

Group type: EXPERIMENTAL
Intervention: ACC-9653 administered alone
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: ACC-9653 administered concomitantly with diazepam
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: ACC-9653
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: ACC-9653 and diazepam administered together
Number of subjects: 9
Study: 7271345

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (1 g in operating room plus 3,578 mg average during the next three days)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Control group (no steroids)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Number of subjects: 114
Study: 30246369

Group type: EXPERIMENTAL
Intervention: Appearance-based messages (images of skin cancer, hyperpigmentation, wrinkles)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Appearance-based messages
Number of subjects: 137
Study: 27550954

Group type: COMPARATOR
Intervention: Crushed immediate-release oxycodone 40 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Crushed ALO-02 40 mg/4.8 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Crushed ALO-02 60 mg/7.2 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intact ALO-02 60 mg/7.2 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Crushed ALO-02 (crushed or intact)
Number of subjects: 0
Study: 26093827

Group type: EXPERIMENTAL
Intervention: Deferasirox (DEFR) administered BID (40 mg/kg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Deferasirox (DEFR) administered once daily (30 or 40 mg/kg)
Number of subjects: 8
Study: 24140268

Group type: EXPERIMENTAL
Intervention: FOLFIRI plus aflibercept
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo plus FOLFIRI
Number of subjects: 0
Study: 22686074

Group type: EXPERIMENTAL
Intervention: Integrative medicine (IM) treatment for diabetic nephropathy
Number of subjects: 170
Study: 20151768

Group type: EXPERIMENTAL
Intervention: Inhaled human insulin (Exubera) titrated once weekly
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Inhaled human insulin (Exubera) titrated twice weekly
Number of subjects: 107
Study: 18052694

Group type: EXPERIMENTAL
Intervention: Endoscopy-aided scaling and root planing (SRP)
Number of subjects: 24

Group type: COMPARATOR
Intervention: SRP alone (control)
Number of subjects: 24